This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Dr Scott Stern and colleagues, M. D. Anderson Cancer Center, Houston, Tex, recently presented their work on the vascular effects of chloroaluminum sulfonated phthalocyanine, a new photosensitizer for photodynamic therapy. The paper was presented at the annual spring meeting of the American Society for Head and Neck Surgery, Palm Beach, Fla. According to these investigators, chloroaluminum sulfonated phthalocyanine has many advantages over the clinically available photosensitizer, dihematoporphyrin ether. These advantages include greater depth of tissue penetration and lack of cutaneous photosensitivity.
Utilizing healing skin incisions of neovascularization in the rat model, the effects of chloroaluminum sulfonated phthalocyanine photodynamic therapy were compared with the effect of chloroaluminum sulfonated phthalocyanine alone, light alone, and no treatment. Results showed a marked increase in vascularity immediately, and up to 12 hours after, photodynamic therapy, as measured by reflectance spectrophotometry. Histologically, the initial increase in vascularity was apparently due to hemorrhage, but marked vasodilation was
WEBER RS. Early Vascular Events in Photodynamic Therapy Utilizing Chloroaluminum Sulfonated Phthalocyanine. Arch Otolaryngol Head Neck Surg. 1990;116(8):902-903. doi:10.1001/archotol.1990.01870080024004